期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肺腺癌胸腔积液沉渣间变性淋巴瘤激酶融合基因蛋白表达与临床病理特征的关系及克唑替尼疗效观察 被引量：3

Relationship between expression of anaplastic lymphoma kinase in pleural effusion and clinicopathological features of patients with lung adenocarcinoma and the response to crizotinib
原文传递
导出
摘要 目的 探讨原发性肺腺癌胸腔积液沉渣间变性淋巴瘤激酶（ALK）蛋白表达与临床病理特征的关系及克唑替尼的治疗效果.方法 回顾性分析2013年9月至2014年1 1月首都医科大学附属北京胸科医院以胸腔积液沉渣包埋标本进行ALK基因重排检测的原发性肺腺癌病例85例,男42例,女43例,年龄30～87岁,平均58岁.采用Ventana全自动免疫组织化学染色和D5F3抗体试剂盒检测ALK蛋白表达,分析表达阳性患者的临床病理特征及克唑替尼的疗效.结果 85例标本中ALK蛋白表达阳性13例（15.3％）;＜60岁患者ALK蛋白阳性12例,≥60岁1例（26.1％,2.6％,x2 =9.015,P=0.002）;男性8例ALK蛋白表达阳性,女性5例（19.1％,11.6％,x2=0.903,P =0.259）;不吸烟组ALK阳性8例,吸烟组5例（17.0％,13.5％,x2=0.379,P=0.827）.13例ALK阳性患者中6例接受表皮生长因子受体（EGFR）基因突变检测,其中5例EGFR为野生型,1例不同肺叶病灶中检测出19外显子突变.13例ALK阳性患者中接受克唑替尼治疗4例,疗效评价均为部分缓解.结论 ALK蛋白阳性多见于晚期肺腺癌中较年轻的患者,ALK阳性患者罕见EGFR基因突变;对原发性肺腺癌合并胸膜转移出现恶性胸腔积液的患者,可根据胸腔积液沉渣包埋标本检测ALK蛋白表达,指导临床靶向治疗. Objective To explore the expression of anaplastic lymphoma kinase （ALK） protein in pleural effusion cells from patients with lung adenocarcinoma and to investigate the relationship between ALK status and the clinicopathological features,and the response to crizotinib.Methods Eighty-five cases were reviewed from Sept.2013-Nov.2014 at Beijing Chest Hospital.There were 42 males and 43 females,with a median age of 58 （30-87）.ALK rearrangements were screened by using immunohistochemistry on Benchmark XT auto-stainer.Results The frequency of ALK positive reactivity was 15.3％ among the 85 patients.The incidence of ALK expression was more frequent in patients ＜ 60 years as compared with patients≥60 years of age（26.1％,2.6％,x2 =9.015,P =0.002）.Among the ALK-positive patients,8 were males and 5 were females （19.1％,11.6％,x2 =0.903,P =0.259）.There were 8 never-smokers and 5 smokers harboring ALK rearrangement（17.0％,13.5％,x2 =0.379,P =0.827）.Among patients with ALK rearrangement,6 received EGFR detection,and 5 showed no EGFR mutation,and 1 showed 19del EGFR mutation.Among the 13 ALK-positive patients,4 received crizotinib therapy,and all showed partial response.Conclusion Patients with lung adenocarcinoma with ALK rearrangement were significantly younger than those with ALK wild-type,and ALK rearrangement was rarely concur with EGFR mutation.Screening ALK fusion protein expression in patients with lung adenocarcinoma by paraffin-embedded sediments of pleural effusion was useful in guide of crizotinib therapy.
作者 穆晶 曲杨 赵丹 董宇杰 王重利 张晨 张莉 张海青
机构地区 首都医科大学附属北京胸科医院北京市结核病胸部肿瘤研究所病理科
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2015年第8期579-583,共5页 Chinese Journal of Tuberculosis and Respiratory Diseases
基金 北京市科委科技计划重大项目（D141100000214003）
关键词 胸腔积液 肺肿瘤 腺癌 间变性淋巴瘤激酶 Pleural effusion Lung neoplasms Adenocarcinoma Anaplastic lymphoma kinase
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics [ J ]. CA Cancer J Clin, 2009, 59(4) :225-249.
  • 2Perez-Moreno P, Brambilla E, Thomas R, et al. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities[J]. Clin Cancer Res, 2012, 18(9) :2443-2451.
  • 3Rosell R, Moran T, Querah C, et al. Screening for epidermal growth factor receptor mutations in lung cancer [ J ]. N Engl J Med, 2009, 361 (10) :958-967 .
  • 4Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer [ J ]. N Engl J Med, 2010, 363 ( 18 ) : 1693-1703.
  • 5Kimura H, Fujiwara Y, Sone T, et al. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib[ J]. Br J Cancer, 2006, 95 (10) : 1390-1395.
  • 6Chu H, Zhong C, Xue G, et al. Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer[ J ]. Oncol Rep, 2013, 30(5): 2311-2315 .
  • 7支修益,陈东红.肺癌新TNM分期系统解析[J].中国医学前沿杂志（电子版）,2010,2(3):32-35. 被引量：4
  • 8Wynes MW, Sholl LM, Dietel M, et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators [ J ] . J Thorac Oncol, 2014, 9(5):631-638.
  • 9Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline ( version 1.1 ) [ J]. Eur J Cancer, 2009, 45 (2) :228-247 .
  • 10Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EMIA-ALK fusion gene in non small cell lung cancer [Jl. Nature, 2007,448(7153) : 561-566.

二级参考文献56

  • 1Matsumura I, Mizuki M, Kanakura Y. Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies. Cancer Sci, 2008, 99(3): 479-485.
  • 2Yang JJ, Zhang XC, Jiang BY, et al. Research prog- ress of individual therapy of advanced NSCLC targeting EML4-ALK fusion gene. Oncology Prog- ress, 2010, 8(6): 538-545.
  • 3Sordella R, Bell DW, Haber DA, et al. Gefitinibsensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science, 2004, 305(5687): 1163-1167.
  • 4Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Kes, 2004, 64(24): 8919-8923.
  • 5Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features asso- ciated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 2005, 97(5): 339-346.
  • 6Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2005, 2(1): el7.
  • 7Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res, 2008, 14(15): 4877-4882.
  • 8Keedy VL, Temin S, Somerfield MR, et al. American society of clinical oncol- ogy provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol, 2011, 29(15): 2121-2127.
  • 9Wu YL, Zhong WZ, Li LY, et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in China's Mainland.J qqaorac Oncol, 2007, 2(5): 430-439.
  • 10Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol, 2011, (suppl): abstr 2501.

共引文献48

同被引文献25

二级引证文献39

中华结核和呼吸杂志
2015年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部